Immunocore Holdings, a Phase 3 biotech developing T cell therapies for cancer and other diseases, raised $258 million by offering 9.9 million ADSs at $26, above the range of $23 to $25. The company offered 19% more ADSs than anticipated at $26 based on an F-1MEF filing late Thursday. The company had also planned to raise an additional $15 million in a concurrent private placement from the Bill & Melinda Gates Foundation.
The Abingdon, UK-based biotech plans to list on the Nasdaq under the symbol IMCR. Goldman Sachs, J.P. Morgan and Jefferies acted as lead managers on the deal.
